Protocol Review and Monitoring System

$258,889P30FY2025CANIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Paper 39627836 Paper 39572569 Paper 39528835 Paper 39482367 Paper 39478233 Paper 39465249 Paper 39329423 Paper 39314411 Paper 39314405 Paper 39314281 Paper 39304451 Paper 39296493 Paper 39241292 Paper 39207369 Paper 39206932 Paper 39187595 Paper 39183582 Paper 39167623 Paper 39149474 Paper 39149321 Paper 39149272 Paper 39087059 Paper 39024547 Paper 38959291 Paper 38945552 Paper 38935405 Paper 38898571 Paper 38783375 Paper 38781024 Paper 38775180 Paper 38727288 Paper 38724670 Paper 38639336 Paper 38632988 Paper 38589567 Paper 38580810 Paper 38553325 Paper 38551497 Paper 38530357 Paper 38496559 Paper 38445546 Paper 38439215 Paper 38422984 Paper 38316601 Paper 38293117 Paper 38290049 Paper 38289325 Paper 38254893 Paper 38253222 Paper 38245855 Paper 38231444 Paper 38206623 Paper 38191243 Paper 38047302 Paper 38022523 Paper 37990024 Paper 37968411 Paper 37968137 Paper 37961724 Paper 37956312 Paper 37935921 Paper 37919899 Paper 37874162 Paper 37852737 Paper 37846210 Paper 37835467 Paper 37830228 Paper 37823708 Paper 37801615 Paper 37782797 Paper 37776536 Paper 37752585 Paper 37706239 Paper 37655662 Paper 37624902 Paper 37611081 Paper 37552479 Paper 37543249 Paper 37537886 Paper 37537835 Paper 37526080 Paper 37487468 Paper 37467022 Paper 37418682 Paper 37418599 Paper 37398244 Paper 37378903 Paper 37370794 Paper 37354070 Paper 37341142 Paper 37301597 Paper 37294412 Paper 37288586 Paper 37285524 Paper 37271662 Paper 37270155 Paper 37269530 Paper 37268519 Paper 37253003 Paper 37232532

Abstract

The Protocol Review and Monitoring System (PRMS) for Winship Cancer Institute of Emory University (Winship), is executed by the Protocol Review and Monitoring Committee (PRMC), which aligns clinical research with research programs and catchment area priorities, and oversees the scientific quality, merit, and feasibility of clinical trials. The PRMC is responsible for review, prioritization, and monitoring to ensure an innovative, impactful, and balanced clinical research portfolio that meets the needs of the Winship catchment area. The PRMC oversees the approval and termination of clinical trials based upon evaluation of scientific validity, feasibility, and accrual. The PRMC operates independently from the Winship Clinical Trials Office (CTO) and the DSMC. PRMC reviews are complementary and non-duplicative of IRB reviews. An initial scientific review is performed by the Winship Treatment Modality Working Groups (TMWG) that meet regularly to review trials for their portfolios. In 2021, the PRMC reviewed 571 clinical trials; 40% were new protocols out of which 32% were expedited reviews and 40% institutional and externally- peer reviewed trials. The PRMC conducts quarterly scientific and accrual progress reviews for active trials. Enhancements to address new CCSG guidelines and further improve the efficacy of the PRMC since Winshipâs last competitive grant renewal include: (1) risk level determination for all treatment trials; (2) prioritization of existing trials portfolio and establishment of review criterion of relevance to the catchment area; (3) annual surveys of Winship members to obtain feedback on PRMC functions and scientific utility; and (4) enhanced training for TMWG members.

View original record on NIH RePORTER →